Toward PET imaging of A2B adenosine receptors: A carbon-11 labeled triazinobenzimidazole tracer. Synthesis and imaging of a new A2B PET tracer

Nuclear Medicine and Biology

Volumn 43, Issue 5, 2016, Pages 309-317

  Petroni, Debora ^a   Giacomelli, Chiara ^b   Taliani, Sabrina ^b   Barresi, Elisabetta ^b   Robello, Marco ^b   Daniele, Simona ^b   Bartoli, Antonietta ^c   Burchielli, Silvia ^d   Pardini, Silvia ^a   Salvadori, Piero A ^a   Da Settimo, Federico ^b   Martini, Claudia ^b   Trincavelli, Maria Letizia ^b   Menichetti, Luca ^a,d  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Fondazione Monasterio   (Italy)

Author keywords

A2B adenosine receptors; Carbon 11; PET; Radiotracer; Substituted 1,2,4 triazino 4,3 a benzimidazoles

Indexed keywords

1 CARBON METHYL 3 PHENYL TRIAZINO[4,3 A]BENZIMIDAZOL 4(1H)ONE C 11; ADENOSINE A2B RECEPTOR; BENZIMIDAZOLE; MOLECULAR SCAFFOLD; TRACER; TRIAZINOBENZIMIDAZOLE; UNCLASSIFIED DRUG; 1-METHYL-3-PHENYLTRIAZINO(4,3-A)BENZIMIDAZOL-4(1H)-ONE; BENZIMIDAZOLE DERIVATIVE; CARBON; MESSENGER RNA; TRIAZINE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STRUCTURE; EX VIVO STUDY; GENE EXPRESSION; IMAGE ANALYSIS; IN VIVO STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RADIATION DOSE DISTRIBUTION; RAT; TISSUE DISTRIBUTION; ANIMAL; CHEMISTRY; CHO CELL LINE; CRICETULUS; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; HUMAN; ISOTOPE LABELING; METABOLISM; PROCEDURES; RADIOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; BENZIMIDAZOLES; CARBON ISOTOPES; CHO CELLS; CRICETINAE; CRICETULUS; GENE EXPRESSION REGULATION; HUMANS; ISOTOPE LABELING; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RATS; RECEPTOR, ADENOSINE A2B; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION; TRIAZINES;

EID: 84960459315     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2016.02.005     Document Type: Article

References (46)

1. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001, 41:775-787.
2. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Klotz K.N., Linden J. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001, 53:527-552.
3. Haskó G., Linden J., Cronstein B., Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008, 7:759-770.
4. Fredholm B.B. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007, 14:1315-1323.
5. Zhou Y., Schneider D.J., Blackburn M.R. Adenosine signaling and the regulation of chronic lung disease. Pharmacol Ther 2009, 123:105-116.
6. Baraldi P.G., Tabrizi M.A., Fruttarolo F., Romagnoli R., Preti D. Recent improvements in the development of A2B adenosine receptor agonists. Purinergic Signal 2009, 5:3-19.
7. Ortore G., Martinelli A. A2B receptor ligands: past, present and future trends. Curr Top Med Chem 2010, 10:923-940.
8. Müller C.E., Jacobson K.A. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta 1808, 2011:1290-1308.
9. Rosentreter U., Henning R., Bauser M., Krämer T., Vaupel A., Hübsch W., et al. Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands 2001, WO Patent.
10. Kuno A., Critz S.D., Cui L., Solodushko V., Yang X.M., Krahn T., et al. Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol 2007, 43:262-271.
11. Kim Y.C., Ji X., Melman N., Linden J., Jacobson K.A. Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem 2000, 43:1165-1172.
12. Ji X., Kim Y.C., Ahern D.G., Linden J., Jacobson K.A. [3H] MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors. Biochem Pharmacol 2001, 61:657-663.
13. Jacobson K.A. Introduction to adenosine receptors as therapeutic targets. Handbook of Experimental Pharmacology 2009, 193:1. Springer-Verlag, Berlin Heidelberg. 10.1007/978-3-540-89615-9. C.N. Wilson, S.J. Mustafa (Eds.).
14. Kalla R.V., Zablocki J. Progress in the discovery of selective, high affinity A2B adenosine receptor antagonists as clinical candidates. Purinergic Signal 2009, 5:21-29.
15. Baraldi P.G., Baraldi S., Saponaro G., Preti D., Romagnoli R., Piccagli L., et al. Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A2B adenosine receptor antagonists. J Med Chem 2012, 55:797-11.
16. Linden J. New insights into the regulation of inflammation by adenosine. J Clin Invest 2006, 116:1835-1837.
17. Feoktistov I., Ryzhov S., Goldstein A.E., Biaggioni I. Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A2B and A3 adenosine receptors. Circ Res 2003, 92:485-492.
18. Feoktistov I., Ryzhov S., Zhong H., Goldstein A.E., Matafonov A., ZengD Biaggioni I. Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension 2004, 44:649-654.
19. Allaman I., Lengacher S., Magistretti P.J., Pellerin L. A2B receptor activation promotes glycogen synthesis in astrocytes through modulation of gene expression. Am J Physiol Cell Physiol 2003, 284:696-704.
20. Johnston-Cox H., Koupenova M., Yang D., Corkey B., Gokce N., Farb M.G., et al. The A2B adenosine receptor modulates glucose homeostasis and obesity. PLoS One 2012, 7:1-9.
21. Zablocki J., Elzein E., Kalla R. A2B adenosine receptor antagonists and their potential indications. Expert Opin Ther Pat 2006, 16:1347-1357.
22. Ryzhov S., Novitskiy S.V., Zaynagetdinov R., Goldstein A.E., Carbone D.P., Biaggioni I., et al. Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia 2008, 10:987-995.
23. Cekic C., Sag D., Li Y., Theodorescu D., Strieter R.M., Linden J. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol 2012, 188:198-205.
24. Chen Y., Epperson S., Makhsudova L., Ito B., Suarez J., Dillmann W., et al. Functional effects of enhancing or silencing adenosine A2b receptors in cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2004, 287:H2478-H2486.
25. Da Settimo F., Primofiore G., Taliani S., Marini A.M., La Motta C., Novellino E., et al. 3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: a new class of selective A1 adenosine receptor antagonists. J Med Chem 2001, 44:316-327.
26. Da Settimo F., Primofiore G., Taliani S., La Motta C., Novellino E., Greco G., et al. A1 adenosine receptor antagonists, 3-aryl[1,2,4]triazino[4,3-a]benzimidazol-4-(10H)-ones (ATBIs) and N-alkyl and N-acyl-(7-substituted-2-phenylimidazo[1,2-a][1,3,5]triazin-4-yl)amines (ITAs): different recognition of bovine and human binding sites. Drug Dev Res 2004, 63:1-7.
27. Novellino E., Cosimelli B., Ehlardo M., Greco G., Iadanza M., Lavecchia A., et al. 2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database searching. J Med Chem 2005, 48:8253-8260.
28. Da Settimo F., Primofiore G., Taliani S., Marini A.M., La Motta C., Simorini F., et al. 5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists. J Med Chem 2007, 50:5676-5684.
29. Cosimelli B., Greco G., Ehlardo M., Novellino E., Da Settimo F., Taliani S., et al. Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem 2008, 51:1764-1770.
30. Taliani S., La Motta C., Mugnaini L., Simorini F., Salerno S., Marini A.M., et al. Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation. J Med Chem 2010, 53:3954-3963.
31. Cosimelli B., Taliani S., Greco G., Novellino E., Sala A., Severi E., et al. Derivatives of benzimidazol-2-ylquinoline and benzimidazol-2-ylisoquinoline as selective A1 adenosine receptor antagonists with stimulant activity on human colon motility. ChemMedChem 2011, 6:1909-1918.
32. Taliani S., Pugliesi I., Barresi E., Simorini F., Salerno S., La Motta C., et al. 3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A2B adenosine receptor antagonists. J Med Chem 2012, 55:1490-1499.
33. Primofiore G., Da Settimo F., Taliani S., Marini A.M., La Motta C., Novellino E., et al. 3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands. J Med Chem 2000, 43:96-102.
34. Ishiwata K., Kimura Y., de Vries E.F.J., Elsinga P.H. PET tracers for mapping adenosine receptors as probes for diagnosis of CNS disorders. Cent Nerv Syst Agents Med Chem 2007, 7:57-77.
35. Bauer A., Ishiwata K. Adenosine receptor ligands and PET Imaging of the CNS. Adenosine receptors in health and disease, handbook of experimental pharmacology 193 2009, 617-642. Springer-Verlag, Berlin Heidelberg. C.N. Wilson, S.J. Mustafa (Eds.).
36. Pike V.W. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci 2009, 30(8):431-440.
37. Laruelle M., Slifstein M., Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol 2003, 5:363-375.
38. Klotz K.N., Hessling J., Hegler J., Owman C., Kull B., Fredholm B.B., et al. Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 1998, 357:1-9.
39. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099-3108.
40. Nordstedt C., Fredholm B.B. A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Anal Biochem 1990, 189:231-234.
41. Petroni D., Berton A., Bettini B., Salvadori P.A. Performances of a TRACERlab FX C synthesis module using a Ni-nanopowder/molecular sieves mixed catalyst. J Radioanal Nucl Chem 2014, 299:2005-2011.
42. Fredholm B.B., IJzerman A.P., Jacobson K.A., Linden J., Müller C.E. International union of basic and clinical pharmacology. LXXXI. nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 2011, 63:1-34.
43. Varani K., Caramori G., Vincenzi F., Adcock I., Casolari P., Leung E., et al. Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:398-406.
44. Dixon A.K., Gubitz A.K., Sirinathsinghji D.J., Richardson P.J., Freeman T.C. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 1996, 118:1461-1468.
45. Gnad T., Scheibler S., von Kügelgen I., Scheele C., Kilić A., Glöde A., et al. Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A receptors. Nature 2014, 516:395-399.
46. Sachdeva S., Gupta M. Adenosine and its receptors as therapeutic targets: an overview. Saudi Pharm J 2013, 21:245-253.